Phase II Trial of Gemcitabine and an Omega-3 Rich Lipid Infusion in Advanced Pancreatic Cancer

被引：0
|
作者：
Arshad, A. [1 ]
Hall, T. [1 ]
Al-Leswas, D. [1 ]
Bilku, D. [1 ]
Cairns, V. [1 ]
Mann, C. [1 ]
Morgan, B. [1 ]
Metcalfe, M. [1 ]
Steward, W. P. [1 ]
Dennison, A. R. [1 ]
机构：
[1] Univ Hosp Leicester, Leicester, Leics, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71910-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [31] A phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer
    Loehr, J. M.
    Bodoky, G.
    Foelsch, U.
    Maerten, A.
    Lilla, C.
    Meyer, I.
    Osinsky, D.
    Szanto, J.
    Lutz, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 386 - 386
  • [32] Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial
    Loehr, M.
    Bodoky, G.
    Folsch, U.
    Marten, A.
    Karrasch, M.
    Lilla, C.
    Meyer, I.
    Osinsky, D.
    Szanto, J.
    Lutz, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Kindler, Hedy Lee
    Wroblewski, Kristen
    Wallace, James A.
    Hall, Michael J.
    Locker, Gershon
    Nattam, Sreenivasa
    Agamah, Edem
    Stadler, Walter M.
    Vokes, Everett E.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 382 - 386
  • [34] Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Kristen Wroblewski
    James A. Wallace
    Michael J. Hall
    Gershon Locker
    Sreenivasa Nattam
    Edem Agamah
    Walter M. Stadler
    Everett E. Vokes
    Investigational New Drugs, 2012, 30 : 382 - 386
  • [35] Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer
    Schmid, P
    Akrivakis, K
    Flath, B
    Grosse, Y
    Sezer, O
    Mergenthaler, HG
    Possinger, K
    ANTI-CANCER DRUGS, 1999, 10 (07) : 625 - 631
  • [36] Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
    Borad, Mitesh J.
    Reddy, Shantan G.
    Bahary, Nathan
    Uronis, Hope E.
    Sigal, Darren
    Cohn, Allen L.
    Schelman, William R.
    Stephenson, Joe, Jr.
    Chiorean, E. Gabriela
    Rosen, Peter J.
    Ulrich, Brian
    Dragovich, Tomislav
    Del Prete, Salvatore A.
    Rarick, Mark
    Eng, Clarence
    Kroll, Stew
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1475 - 1481
  • [37] Advanced breast cancer: A phase II trial with gemcitabine (GEM)
    Possinger, K
    Kaufmann, M
    Helsing, M
    Coleman, R
    Blatter, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 369 - 369
  • [38] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    Feliu, J.
    Borrega, P.
    Leon, A.
    Lopez-Gomez, L.
    Lopez, M.
    Castro, J.
    Belda-Iniesta, C.
    Barriuso, J.
    Martinez, V.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 215 - 221
  • [39] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    J. Feliu
    P. Borrega
    A. León
    L. López-Gómez
    M. López
    J. Castro
    C. Belda-Iniesta
    J. Barriuso
    V. Martínez
    M. González-Barón
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 215 - 221
  • [40] Phase II study of gemcitabine and Flutamide in advanced pancreatic cancer.
    Mayer, A
    Shaw, J
    D'Ath, S
    Price, P
    Blesing, C
    Corrie, P
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
12345